Chesley Taft & Associates LLC boosted its stake in Allergan PLC. (NYSE:AGN) by 36.4% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 13,059 shares of the company’s stock after buying an additional 3,482 shares during the period. Chesley Taft & Associates LLC’s holdings in Allergan PLC. were worth $3,175,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Israel Discount Bank of New York purchased a new position in Allergan PLC. during the first quarter valued at $988,000. Trust Co. of Vermont boosted its position in Allergan PLC. by 62.8% in the first quarter. Trust Co. of Vermont now owns 2,875 shares of the company’s stock valued at $687,000 after buying an additional 1,109 shares during the last quarter. Capital Planning Advisors LLC boosted its position in Allergan PLC. by 79.3% in the first quarter. Capital Planning Advisors LLC now owns 3,674 shares of the company’s stock valued at $878,000 after buying an additional 1,625 shares during the last quarter. First Long Island Investors LLC purchased a new position in Allergan PLC. during the first quarter valued at $4,826,000. Finally, Rehmann Capital Advisory Group boosted its position in Allergan PLC. by 15.4% in the first quarter. Rehmann Capital Advisory Group now owns 1,780 shares of the company’s stock valued at $425,000 after buying an additional 237 shares during the last quarter. 83.63% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Allergan PLC. (NYSE:AGN) traded up 0.9060% during trading on Tuesday, reaching $224.9901. 735,926 shares of the company traded hands. The firm has a 50 day moving average of $242.74 and a 200 day moving average of $238.85. The stock has a market capitalization of $75.22 billion, a PE ratio of 6.8549 and a beta of 1.16. Allergan PLC. has a 52 week low of $184.50 and a 52 week high of $256.80. Allergan PLC. also was the target of unusually large options trading activity on Monday. Traders acquired 5,214 put options on the company. This is an increase of 127% compared to the typical daily volume of 2,298 put options.

Allergan PLC. (NYSE:AGN) last posted its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The business had revenue of $4.01 billion for the quarter, compared to analysts’ expectations of $3.95 billion. During the same period in the prior year, the company posted $3.35 EPS. The business’s revenue for the quarter was up 8.8% on a year-over-year basis. On average, equities analysts predict that Allergan PLC. will post $16.27 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be paid a dividend of $0.70 per share. The ex-dividend date of this dividend is Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.26%. Allergan PLC.’s dividend payout ratio (DPR) is presently 9.95%.

WARNING: This piece was originally published by Daily Political and is owned by of Daily Political. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://www.dailypolitical.com/2017/08/22/allergan-plc-agn-shares-bought-by-chesley-taft-associates-llc.html.

A number of research firms recently commented on AGN. Cowen and Company set a $400.00 target price on Allergan PLC. and gave the company a “buy” rating in a research note on Thursday, June 8th. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Allergan PLC. in a research note on Thursday, May 25th. Mizuho reduced their price objective on Allergan PLC. from $275.00 to $267.00 and set a “buy” rating on the stock in a research note on Friday, June 9th. Cantor Fitzgerald began coverage on Allergan PLC. in a research note on Friday, June 16th. They set a “neutral” rating and a $231.00 price objective on the stock. Finally, Zacks Investment Research raised Allergan PLC. from a “hold” rating to a “buy” rating and set a $270.00 price objective on the stock in a research note on Tuesday, July 11th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have given a buy rating to the company’s stock. Allergan PLC. currently has a consensus rating of “Buy” and a consensus price target of $275.49.

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.